Page last updated: 2024-08-23

bromocriptine and Dyslipidemia

bromocriptine has been researched along with Dyslipidemia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Krysiak, R; Okopień, B; Szkróbka, W1
Carvalho, JC; Conceição, EP; de Oliveira, E; Lima, NS; Lisboa, PC; Moura, EG; Nogueira-Neto, JF; Peixoto-Silva, N1
Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W1

Other Studies

3 other study(ies) available for bromocriptine and Dyslipidemia

ArticleYear
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:1

    Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopamine Agonists; Dyslipidemias; Female; Fenofibrate; Humans; Hyperprolactinemia; Hypolipidemic Agents; Lipids; Middle Aged; Prolactin; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Young Adult

2019
Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?
    Life sciences, 2014, Jan-24, Volume: 95, Issue:1

    Topics: Adiposity; Animals; Bromocriptine; Dyslipidemias; Female; Glucose; Injections, Intraperitoneal; Insulin Resistance; Intra-Abdominal Fat; Liver; Liver Diseases; Male; Obesity; Oxidation-Reduction; Oxidative Stress; Prolactin; Rats; Rats, Wistar; Time Factors; Weaning

2014
The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:1

    Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Diseases; Middle Aged; Pilot Projects; Risk Factors; Treatment Outcome; Young Adult

2016